acarix English, Interim, IR, Listing Regulation, News, Q1, Regulatory, Report November 18, 2024 11 May 2023 Acarix AB (publ) publishes Interim Report, January – March 2023 2023 is off to a good startIn the first quarter of 2023 our strategy delivered important results with a breakthrough order from the lar... Continue reading
acarix Interim, IR, Listing Regulation, News, Q1, Regulatory, Report, Swedish November 18, 2024 11 May 2023 Acarix AB (publ) publicerar delårsrapport, januari – mars 2023 2023 har börjat braUnder första kvartalet 2023 levererade vi viktiga delresultat med en genombrottsorder från den st&ou... Continue reading
acarix Annual, English, IR, Listing Regulation, News, Regulatory, Report November 18, 2024 20 Apr 2023 Acarix AB’s Annual Report 2022 Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces that the Annual Report for 2022 is available as a pdf on... Continue reading
acarix Annual, IR, Listing Regulation, News, Regulatory, Report, Swedish November 18, 2024 20 Apr 2023 Acarix AB’s Årsredovisning 2022 Acarix, ledare inom akustisk och AI-baserad hjärtdiagnostik, meddelar idag att årsredovisning för 2022 finns tillgä... Continue reading
acarix Interim, IR, Listing Regulation, News, Regulatory, Report, Swedish, Yearend November 18, 2024 16 Feb 2023 Acarix AB (publ) publicerar Bokslutskommuniké 2022 Strategiskt skifte till fullt kommersiellt fokus på USA-marknaden nu på platsNär vi summerar 2022 blir det tydligt att... Continue reading
acarix English, Interim, IR, Listing Regulation, News, Regulatory, Report, Yearend November 18, 2024 16 Feb 2023 Acarix AB (publ) publishes Year-End Report 2022 Strategic shift towards full commercial focus on the US market now in placeAs we sum up 2022, it becomes clear that Acarix has in a sho... Continue reading
acarix English, Interim, IR, MAR, News, Q3, Regulatory, Report November 18, 2024 16 Nov 2022 Full focus on the US market with strong interest from healthcare providers, reimbursement code in place and collaboration with ACC Acarix is now taking an important strategic step, putting full commercial focus on the US market. We have the key building blocks in pl... Continue reading
acarix Interim, IR, MAR, News, Q3, Regulatory, Report, Swedish November 18, 2024 16 Nov 2022 Fullt fokus på USA med stort intresse från sjukvården, egen reimbursementkod på plats och samarbete med ACC Acarix tar nu ett viktigt strategiskt kliv och lägger fullt kommersiellt fokus på USA-marknaden. Vi har de viktiga byggstena... Continue reading
acarix English, Interim, IR, Listing Regulation, News, Q2, Regulatory, Report November 18, 2024 25 Aug 2022 Acarix AB (publ) publishes Interim Report, January – June 2022 Significant interest and positive developments in the US marketWe can now conclude that our Go-To-Market strategy in the USA has starte... Continue reading
acarix Interim, IR, Listing Regulation, News, Q2, Regulatory, Report, Swedish November 18, 2024 25 Aug 2022 Acarix AB (publ) publicerar delårsrapport, januari – juni 2022 Stort intresse och positiv utveckling på den amerikanska marknadenVi kan nu konstatera att vår Go-To-Market strategi i USA ... Continue reading
acarix Interim, IR, Listing Regulation, News, Q1, Regulatory, Report, Swedish November 18, 2024 11 May 2022 Acarix AB (publ) publicerar delårsrapport, januari – mars 2022 Pressmeddelande Malmö, 11 maj 2022 Acarix AB (publ) publicerar delårsrapport, januari - mars 2022 Ök... Continue reading
acarix English, Interim, IR, Listing Regulation, News, Q1, Regulatory, Report November 18, 2024 11 May 2022 Acarix AB (publ) publishes Interim Report, January – March 2022 Press release Malmö, Sweden, May 11, 2022 Acarix AB (publ) publishes Interim Report, January – March 2022 ... Continue reading